Core Viewpoint - Axsome Therapeutics has experienced a decline in share price of approximately 6.6% since its last earnings report, underperforming the S&P 500, raising questions about the potential for continued negative trends or a breakout ahead of the next earnings release [1][2]. Financial Performance - In Q4 2025, Axsome reported a loss of 71 cents per share, which was wider than the Zacks Consensus Estimate of a loss of 70 cents, compared to a loss of 96 cents per share in the same quarter the previous year [3]. - Total revenues surged by 65% year over year to $196 million in Q4, exceeding the Zacks Consensus Estimate of $193 million, primarily driven by strong sales of Auvelity and other marketed drugs [4]. - Net product revenues reached $194.7 million in Q4, reflecting a 66% year-over-year increase, with royalty revenues totaling $1.3 million [5]. Product Sales Breakdown - Auvelity sales amounted to $155.1 million, up 68% from the previous year, surpassing the Zacks Consensus Estimate of $151 million, with approximately 225,000 prescriptions recorded, marking an 8% sequential increase and a 42% year-over-year increase [6]. - Sunosi generated net product sales of $36.7 million in Q4, a 40% increase from the previous year, with total prescriptions growing 11% year over year to 54,000 [7]. - Symbravo recorded sales of $4.1 million in Q4, an increase from $2.1 million in Q3 2025 [7]. Expense Overview - Research and development expenses were $48.8 million, down 11.3% from the previous year, attributed to the completion of label expansion studies [8]. - Selling, general, and administrative expenses totaled $169.3 million, up 49.4% year over year, driven by increased commercial activities for Auvelity and ongoing launch activities for Symbravo [9]. Cash Position - As of December 31, 2025, Axsome had cash and cash equivalents of $322.9 million, slightly down from $325.3 million as of September 30, 2025 [9]. Market Sentiment - Estimates for Axsome have trended downward over the past month, with a consensus estimate shift of -49.28% [10]. - The company currently holds a strong Growth Score of A but lags in Momentum and Value Scores, receiving an overall VGM Score of C [12]. - The downward trend in estimates has led to a Zacks Rank of 4 (Sell), indicating expectations of below-average returns in the coming months [13].

Company Performance - Auvelity ended the previous year with annualized revenue just above $600 million, marking its third full year since launch in 2022, indicating strong performance in the market [1] - The company is outpacing peers in the industry, reflecting effective marketing strategies and execution [1] Sales Force and Market Access - The sales force has expanded from 160 to 260 in 2024, and further to 300 in 2025, which is expected to enhance market penetration [1] - Current market access coverage stands at 86%, showing improvement over time and contributing to revenue growth [1]

Axsome Therapeutics Conference Call Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Industry**: Biopharmaceuticals, focusing on central nervous system (CNS) disorders - **Mission**: Develop transformative medicines for CNS conditions affecting hundreds of millions globally [6][7] Key Financial Highlights - **2025 Performance**: - Auvelity generated over **$500 million** in revenue, marking its third year since launch - Total sales for the company approached **$640 million** [7][8] - **2026 Expectations**: - Anticipation of a PDUFA date for Auvelity in Alzheimer's disease agitation on **April 30, 2026** [7][8] - **Team Expansion**: Plans to increase the workforce from **300 to 600** employees [8] Product Portfolio - **Current Products**: - Three on-market products: Auvelity, Sunosi, and SYMBRAVO - Peak sales potential for these products estimated between **$2 billion to $5 billion** [10][18] - **Pipeline**: - Five differentiated product candidates with **seven late-stage clinical trials** [10][11] - Total peak sales potential for pipeline conditions exceeds **$16 billion**, affecting over **150 million patients** [11][12] Product-Specific Insights - **Auvelity**: - Approved for major depressive disorder; expected peak sales for Alzheimer's agitation between **$1.5 billion to $3 billion** [14][34] - Currently holds **86%** market access coverage, with plans to enhance primary care market penetration [22][23] - **Sunosi**: - Revenue growth of **40% year-over-year**; currently generating **$300 million to $500 million** [27][28] - **SYMBRAVO**: - Launched in June 2025; initial growth observed with plans to improve payer coverage [19][30] Clinical Trials and Future Developments - **AXS-05**: - Undergoing review for Alzheimer's disease agitation; three positive trials supporting the application [34][36] - **AXS-12**: - NDA submission for cataplexy in narcolepsy imminent [41] - **Solriamfetol**: - Involved in multiple phase 3 trials for ADHD, major depressive disorder with excessive daytime sleepiness, binge eating disorder, and shift work disorder [37][39][40] Financial Position - **Cash Position**: - **$323 million** on the balance sheet, with a small debt of around **$190 million** [45] - **Revenue Growth**: - Revenues grew three times faster than operating expenses in 2025, with expectations for continued operating leverage in 2026 [45][46] Strategic Focus for 2026 - **Growth Initiatives**: - Focus on commercial performance, R&D advancement, and team expansion to support business growth [17][18] - **Market Access**: - Continued efforts to improve formulary access and expand into primary care markets [22][23] Conclusion - Axsome Therapeutics is well-positioned for growth in 2026, with a strong product pipeline, significant revenue potential, and strategic initiatives aimed at expanding market access and enhancing operational efficiency [45][46]

Core Insights - Popular companies may not always represent the best investment opportunities, while lesser-known firms can be undervalued and present attractive prospects for long-term investors [1] Group 1: Axsome Therapeutics - Axsome Therapeutics' stock has more than doubled in value over the past five years, driven by clinical and commercial advancements, particularly with its leading candidate Auvelity, approved for treating depression [4] - In 2025, Axsome's revenue increased by 66% to $638.5 million, and its net loss per share improved to $3.68 from $5.99 in 2024 [5] - The company targets large, underserved markets, with potential sales for Auvelity in Alzheimer's disease agitation estimated between $1.5 billion to $3 billion, contributing to a projected peak sales exceeding $16 billion across its late-stage pipeline [6][7] Group 2: Madrigal Pharmaceuticals - Madrigal Pharmaceuticals received FDA approval for Rezdiffra in 2024, the first treatment for metabolic dysfunction-associated steatohepatitis (MASH), leading to strong commercial progress [8] - The company generated $958.4 million in revenue in the last year with Rezdiffra as its sole product, a significant increase from $180.1 million in 2024 [8]

Axsome Therapeutics Conference Call Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Date**: March 09, 2026 - **Key Speakers**: Mark Jacobson (COO), Nick Pizzie (CFO) Key Points Auvelity Performance and Strategy - Auvelity annualized revenue at the end of 2025 was just over **$600 million**, marking its third full year since launch in 2022, outperforming peers in the market [6][7] - The sales force expanded from **160** to **300** representatives in 2025, with plans to double to **600** in 2026, focusing on Major Depressive Disorder (MDD) and the anticipated approval for Agitation in Alzheimer’s Disease (ADA) [7][8] - Peak sales projections for Auvelity are estimated between **$1 billion** to **$3 billion** for MDD and **$1.5 billion** to **$3 billion** for ADA [7] - Market access has improved to **86%** coverage of total lives, with **100%** coverage in the government channel and **78%** on the commercial side [21][22] - Direct-to-consumer (DTC) advertising began in September 2025, with adjustments made based on learnings from the initial campaign [18][19] Clinical and Market Dynamics - Auvelity's clinical profile shows a distinct safety and tolerability profile, with over **50%** of prescriptions now coming from first and second-line treatments [8][9] - The product is gaining traction in primary care, with about **33%** of scripts originating from this sector [9] - The company is reallocating resources from DTC to expand the sales team, anticipating that this will enhance the effectiveness of future DTC campaigns [18][19] Upcoming Indications and Trials - The PDUFA date for ADA is set for **April 30, 2026**, with preparations underway for potential FDA approval [23][24] - Axsome is also exploring a smoking cessation indication for Auvelity, with clinical operations set to begin soon [30][32] Symbravo Launch - Symbravo is performing well in the migraine space, with a focus on later-line treatment due to payer management [36][37] - The sales force for Symbravo is currently **100 reps**, with a strategy to refine the launch based on early utilization data [40][41] - Market access for Symbravo is around **50%** covered lives, with recent contracts signed to improve access [45] Sunosi Growth - Sunosi has seen a **40%** year-over-year growth, supported by a dedicated team of **70 reps** [55][57] - The company is optimistic about further accelerating revenue through four indications currently in development [57] AXS-14 and AXS-17 Developments - AXS-14 (esreboxetine) is targeting the fibromyalgia market, with a new phase 3 trial launched after a previous Refuse to File due to trial design issues [87][89] - AXS-17 is a new product for epilepsy, with plans for phase 2 enabling work in 2026, focusing on unmet needs in the epilepsy space [106][107] AXS-12 Submission - AXS-12, targeting narcolepsy with a focus on cataplexy, is at the NDA stage, with submission expected soon [121] Additional Insights - The company is strategically focusing on expanding its pipeline and market presence while addressing regulatory feedback to enhance product approvals [89][90] - There is a strong emphasis on understanding market dynamics and patient needs to drive product utilization and acceptance [41][57]

Core Thesis - Axsome Therapeutics, Inc. is positioned as a differentiated neuro-focused biotech with multiple commercial assets and a late-stage pipeline targeting large, underserved markets [3][6] - The stock was trading at $163.19 with a forward P/E of 370.37, indicating high investor expectations [1][3] Commercial Products - Axsome has three products on the market, with Auvelity for major depressive disorder being the primary growth driver, showing a 69% sales increase in Q3 and projected peak sales of approximately $2 billion [4][6] - Sunosi, indicated for sleep apnea, experienced a 35% growth last quarter, while Symbravo for acute migraines is expected to reach a peak opportunity of $400 million [4][6] Pipeline Potential - The pipeline includes AXS-12 for narcolepsy, projected as a potential $500 million product, and AXS-05 for Alzheimer's agitation, which could exceed $1.5 billion in peak sales with possible approval in the first half of 2026 [5] - Another Phase III candidate targeting ADHD may represent an additional $1 billion opportunity [5] Financial Performance - Overall sales have risen 63% and 72% in the past two quarters, with analysts forecasting over 50% growth next year [6] - Breakeven is expected in 2026 as the company scales, indicating a positive trajectory towards profitability [6] Market Sentiment - The stock has recently broken to new highs after a nine-month consolidation period, suggesting improving market sentiment [6] - The combination of accelerating revenues and multiple regulatory catalysts presents a compelling growth narrative with significant upside potential [6][8]

Core Thesis - Axsome Therapeutics, Inc. is positioned as a differentiated neuro-focused biotech with multiple commercial assets and a late-stage pipeline targeting large, underserved markets [3][6] - The stock was trading at $163.19 with a forward P/E of 370.37, indicating high investor expectations [1][3] Commercial Products - Axsome's lead product, Auvelity for major depressive disorder, saw sales increase by 69% in the third quarter, with projected peak sales of approximately $2 billion [4] - Sunosi, indicated for sleep apnea, experienced a 35% growth last quarter, while Symbravo for acute migraines is expected to reach a peak opportunity of $400 million [4] - Overall sales have risen by 63% and 72% in the past two quarters, with analysts forecasting over 50% growth next year [6] Pipeline Potential - The pipeline includes AXS-12 for narcolepsy, projected as a potential $500 million product, and AXS-05 for Alzheimer's agitation, which could exceed $1.5 billion in peak sales [5] - Another Phase III candidate targeting ADHD and related indications may represent an additional $1 billion opportunity [5] Financial Outlook - Breakeven is expected in 2026 as scale improves, indicating a path toward profitability [6] - The stock has recently broken to new highs after a nine-month consolidation, suggesting improving market sentiment [6]

Axsome Therapeutics FY Conference Summary Company Overview - **Company**: Axsome Therapeutics (NasdaqGM:AXSM) - **Event**: FY Conference held on February 25, 2026 Core Business and Product Performance - **Product**: Auvelity for Major Depressive Disorder (MDD) - **Sales Achievement**: Over $500 million in sales in 2025, three years post-launch [2] - **Salesforce Expansion**: Increased from 300 to 600 sales representatives to enhance market penetration, particularly in primary care [4] - **Market Access**: Improved access with 86% of covered lives, including 100% in the government channel [7][8] - **First Line Prescriptions**: 50% of total prescriptions are for first line or first switch patients [8] Market Dynamics and Growth Drivers - **Uptake Drivers**: Increased awareness, trial engagement, and a differentiated product profile leading to positive patient outcomes [9] - **Retention Rates**: Currently tracking in line with typical antidepressant persistence, with over 50% of patients being first line or first switch [11][12] - **Alzheimer's Disease Agitation (ADA) Opportunity**: Anticipation of FDA's PDUFA date on April 30, 2026, for Auvelity's indication in Alzheimer's agitation [15] Clinical Data and Regulatory Insights - **Clinical Trials**: Four controlled trials conducted, with three positive outcomes supporting efficacy and safety [22][23] - **Safety Profile**: No significant safety concerns noted, particularly regarding falls or mortality in the elderly population [24] - **Market Size for ADA**: Approximately 5 million Alzheimer's patients experience agitation, with 20 million scripts written annually, predominantly off-label [20] Go-to-Market Strategy - **Pre-launch Activities**: Non-branded campaigns to raise awareness about Alzheimer's agitation and education for healthcare providers [27] - **Reimbursement Strategy**: Full coverage anticipated for Medicare Part D, which constitutes over 70% of total scripts for Alzheimer's agitation [28] - **Expected GTN Improvement**: Anticipated better gross-to-net (GTN) for ADA scripts compared to MDD due to the nature of Medicare Part D [28] Future Catalysts and Pipeline - **Upcoming Trials**: Ongoing trials for binge eating disorder (BED) and shift work disorder, with top-line results expected in the second half of 2026 [35][36] - **New Product AXS-12**: NDA submission imminent, leveraging existing sales force for potential launch in narcolepsy [39] - **New Asset AXS-17**: Recently in-licensed for epilepsy, complementing the existing CNS pipeline [42] Financial Outlook - **Cash Flow Positivity**: Near-term expectations for cash flow positivity remain unchanged, with recent quarters showing close to cash flow positive results [53][54] - **Sales Projections**: Peak sales for Auvelity projected between $2.5 billion and $6 billion, viewed as achievable based on current market dynamics [34] Conclusion - Axsome Therapeutics is positioned for significant growth with its product Auvelity, particularly in the MDD and Alzheimer's agitation markets. The company is actively expanding its sales force, improving market access, and preparing for upcoming product launches and regulatory approvals. The financial outlook remains positive, with a focus on achieving cash flow positivity and leveraging its robust pipeline for future growth.

Core Insights - Axsome Therapeutics reported a loss of 71 cents per share in Q4 2025, which was wider than the expected loss of 70 cents, compared to a loss of 96 cents per share in the same quarter last year [1][6] - The company's total revenues increased by 65% year over year to $196 million in Q4, surpassing the consensus estimate of $193 million, primarily driven by strong sales of Auvelity [2][6] Financial Performance - Total revenues in Q4 included product revenues from Auvelity, Sunosi, and Symbravo, with net product revenues reaching $194.7 million, a 66% increase year over year [3] - Auvelity sales were $155.1 million, up 68% from the previous year, exceeding the consensus estimate of $151 million [4][6] - Sunosi's net product sales were $36.7 million, reflecting a 40% increase year over year, with total prescriptions growing 11% to 54,000 [7] Expenses and Cash Position - Research and development expenses were $48.8 million, down 11.3% from the previous year due to the completion of label expansion studies [10] - Selling, general, and administrative expenses rose to $169.3 million, a 49.4% increase year over year, attributed to higher commercial activities for Auvelity and ongoing launch activities for Symbravo [11] - As of December 31, 2025, Axsome had cash and cash equivalents of $322.9 million, slightly down from $325.3 million at the end of Q3 2025, which is expected to fund operations into cash flow positivity [12] Full-Year Results - For the full year 2025, Axsome generated revenues of $638.5 million, a 66% growth year over year, with an adjusted loss of $3.68 per share, an improvement from a loss of $5.99 in the previous year [13] Pipeline Developments - Axsome is conducting label expansion studies for Auvelity and has submitted a supplemental new drug application for AXS-05 for Alzheimer's disease agitation, with a decision expected by April 30, 2026 [14] - The company plans to initiate a pivotal phase II/III study of AXS-05 for smoking cessation in Q2 2026, and is evaluating AXS-12 and AXS-14 for multiple CNS indications [15][16] - AXS-12 is in late-stage studies for narcolepsy, with a potential NDA submission planned for the first quarter of 2026 [16] - Axsome is also conducting phase III studies for solriamfetol targeting ADHD, MDD, binge eating disorder, and excessive sleepiness associated with shift work disorder, with data expected in 2026 and 2027 [17][18]

Core Insights - The company achieved 66% annual revenue growth driven by Auvelity's rapid uptake, surpassing $500 million in net sales in its third full year of launch [1] - Auvelity's outperformance is attributed to its distinct clinical profile and fast onset of action, allowing it to grow 42% year-over-year while the broader antidepressant market remained flat [1] - The primary care prescriber base for Auvelity has expanded, now representing approximately one-third of all prescribers and is the fastest-growing segment [1] Sales and Market Expansion - A major sales force expansion has been initiated to approximately 600 representatives to support continued growth in Major Depressive Disorder (MDD) and prepare for the potential Alzheimer's disease agitation (ADA) launch [1] - Sunosi reported accelerating momentum with 40% fourth-quarter revenue growth, driven by increased depth among existing writers in both the Obstructive Sleep Apnea (OSA) and narcolepsy markets [1] - The company successfully contracted with a third large commercial Group Purchasing Organization (GPO) for Cymbravo, enabling negotiations with all major commercial payers and Pharmacy Benefit Managers (PBMs) to improve market access [1] Strategic Acquisitions - The company acquired AXS-17, a novel GABA-A modulator, to leverage its expertise in Central Nervous System (CNS) and existing safety data for a new development program in epilepsy [1]